The European Medicines Agency selected TrialAssure’s ANONYMIZE platform as an official tool to redact public clinical trial documents under Policy 0043. EMA will deploy AI-assisted detection with expert oversight to anonymize clinical dossiers before they are posted across the EU and EEA. TrialAssure said the system handles sensitive information across documents, datasets, and images while preserving scientific utility and maintaining auditability. EMA framed the selection as part of its transparency push alongside data protection requirements. For biotech, the change affects how market authorization holders prepare and submit dossiers intended for public disclosure—potentially standardizing anonymization workflows and reducing manual burden.